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The growth factor progranulin has emerged in recent years as a critical regulator of 
transformation in several cancer models, including breast cancer, glioblastomas, leu-
kemias, and hepatocellular carcinomas. Several laboratories, including ours, have also 
demonstrated an important role of progranulin in several genitourinary cancers, including 
ovarian, endometrial, cervical, prostate, and bladder tumors, where progranulin acts as 
an autocrine growth factor thereby modulating motility and invasion of transformed cells. 
In this review, we will focus on the mechanisms of action and regulation of progranulin 
signaling in genitourinary cancers with a special emphasis on prostate and bladder 
tumors.
Keywords: progranulin, bladder and prostate cancer, motility, anchorage-independent growth, tumor formation 
in vivo
iNTRODUCTiON
Progranulin, also known as proepithelin, granulin–epithelin precursor, acrogranin, and PC cell-
derived growth factor, is a secreted glycoprotein with dual cellular roles, both as a growth factor 
regulating cell proliferation and wound repair and as a component of the transforming machinery 
in several cancer systems (1–3). Progranulin regulates inflammation and neurodegeneration (4) and 
has been linked to the development of frontotemporal dementia (FTD) (4).
Progranulin contains seven and a half granulin-like domains, which are ~6 kDa peptides called 
granulins (granulin A to G and paragranulin). These domains contain highly conserved tandem 
repeats of 12-cysteine residues, with the exception of granulin G, which has only 10 cysteine residues. 
The progranulin precursor is a 68.5-kDa protein of 593 amino acids, which migrates at ~88 kDa on 
Western immunoblot due to glycosylation (5).
Historically, granulins were first discovered as a novel class of leukocyte peptides with cytokine-
like activities (6, 7). The progranulin precursor protein was later purified from PC cell-derived 
conditioned medium by Zhou et al. (8), who demonstrated the function of progranulin as mito-
gen and an autocrine growth factor for cancer cell lines. This precursor protein was identical to 
a growth-promoting factor later purified by Dr. Baserga’s group from the conditioned media of 
BRL-3A rat liver cells (8), which was able to induce cell proliferation of R− cells, derived from mice 
with a targeted deletion of the insulin-like growth factor receptor (IGF-IR) gene (9). Significantly, 
progranulin was the only known growth factor able to bypass the requirement for the IGF-IR, thus 
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promoting growth of R− cells (10). As demonstrated by He et al., 
progranulin  overexpression in adrenal carcinoma and renal epi-
thelial cells resulted in enhanced progranulin secretion, increased 
mitogenesis, and tumorigenesis (11). Progranulin has been 
shown to enhance proliferation and promote tumor growth in 
several cancer cell lines, such as breast, gastrointestinal, hepatic, 
lung, and genitourinary cancers. In this manuscript, we review 
progranulin’s dual roles as a novel transforming growth factor and 
a clinical diagnostic and prognostic biomarker in genitourinary 
cancers.
PROGRANULiN iN OvARiAN CANCeR
Ovarian cancer (OC) is the deadliest gynecological cancer and is 
the fourth leading cause of cancer-related deaths in women (12). 
While current treatment with surgery and chemotherapy can 
manage early stage disease, patients with late stage disease often 
recur and develop distant metastases. From the initial diagnosis, 
the median 10-year survival is only about 40% (13). Thus, it is 
very important to identify novel predictors of ovarian tumor 
progression.
Progranulin action in OC has been well characterized. Jones 
et al. (14) compared progranulin expression between low malig-
nant potential and invasive ovarian tumors and demonstrated 
that progranulin expression was upregulated in invasive OC 
compared to low-grade tumors (15), suggesting that progranulin 
expression may be predictive of tumor progression. Progranulin 
mRNA and protein expression levels were significantly higher 
in tissue samples obtained from OC when compared to benign 
and normal ovarian tissues (15–17). Furthermore, progranulin 
expression level was correlated with higher stage and worse 
prognosis in OC patients (16–20).
Furthermore, numerous in  vitro and in  vivo studies have 
demonstrated the role of progranulin in promoting proliferation, 
resistance to apoptosis, and motility of OC cells, where pro-
granulin activates mitogen-activated protein kinase (MAPK) and 
MMP-2 signaling (14, 17, 20–22).
Another potential serum marker for OC is serum leukocyte 
protease inhibitor (SLPI), a serine protease inhibitor protein, 
whose levels are elevated in serum derived from patients with 
OC (23). Significantly, SLPI protects progranulin from serine 
proteases and cleavage into mature granulins (24). Devoogdt 
et  al. demonstrated that SLPI overexpression protected pro-
granulin from elastase-mediated degradation and increased OC 
growth and survival, both in vitro and in vivo (25, 26). Han et al. 
reported that among progranulin, SLPI, and the FDA approved 
serum biomarkers HE4 and CA125, progranulin was the only 
biomarker independently associated with poor prognosis in OC 
patients in remission after initial surgical cytoreduction and 
chemotherapy (18).
PROGRANULiN iN CeRviCAL AND 
eNDOMeTRiAL CANCeR
Cervical cancer is the third most common cancer among women 
worldwide and the third most common genitourinary cancer in 
United States (12). Human papillomavirus (HPV) infection is the 
prevalent cause of cervical cancer as in fact over 99% of cervical 
cancers are positive for HPV (27). However, only a small fraction 
of women infected by HPV develops cervical cancer suggesting 
that other factors contribute to its progression.
Progranulin overexpression or recombinant progranulin 
protein stimulated transformation of HPV16-immortalized 
cervical mucosa epithelial H8 cells in vitro and in vivo (28, 29). 
On the contrary, inhibition of progranulin expression by siRNA 
approaches inhibited growth (28, 30).
Endometrial cancer is the most common genital cancer 
among women in United States, with an estimated 60,050 new 
cases in 2016 (12). The risk factors are related to an increase in 
circulating estrogens secondary to obesity, chronic anovulation 
and nulliparity estrogen replacement therapy, and tamoxifen 
use. Endometrial cancer tissues showed upregulated progranu-
lin expression in association with estrogen receptor (31), and 
progranulin expression level was increased after estradiol and/
or tamoxifen treatment in vitro (31). Similar to cervical cancer, 
inhibition of progranulin with shRNAs resulted in decreased 
endometrial cancer cell proliferation (31).
These results suggest that in endometrial cancer progranulin 
may work in estradiol-dependent fashion and mediate, at least 
in part, estrogen receptor-dependent biological responses. This 
is reminiscent of progranulin action in breast cancer, where pro-
granulin (PCDGF/granulin precursor) expression is stimulated 
by estradiol (32) and progranulin regulates estrogen-dependent 
mitogenesis (33).
PROGRANULiN ACTiON iN  
BLADDeR CANCeR
Bladder cancer is the fourth most common cancer in men in 
developed countries, with high recurrence rates of around 60% 
after treatment (12, 34, 35). The vast majority of early stages blad-
der tumors present as low-grade non-invasive papillary tumors 
(Ta stage). The remaining comprises tumors that have penetrated 
the basement membrane but not invaded the muscle layer of 
the bladder wall (T1 stage) and muscle-invasive tumors (T2–T4 
stages) (36). The prognosis for low-grade tumors is generally 
good but about 15% of low-grade tumors progress to invasive 
disease. For invasive tumors, patient survival is ~50% at 5 years 
(37). Invasive tumors are frequently associated with metastases, 
which have a 5-year survival rate of 6% (37). However, despite 
the significant clinical impact of bladder cancer, there is still an 
urgent need to discover drivers of disease progression and novel 
therapeutic targets.
In recent years, our laboratories have established that pro-
granulin plays a critical role in bladder cancer by regulating 
bladder cancer cell motility, invasion, anchorage-independent 
growth, and tumor formation in vivo (38–41).
We initially demonstrated that recombinant human pro-
granulin did promote migration, wound closure, and invasion 
of urothelial cancer cells (42). Progranulin-mediated biological 
responses required the activation of the MAPK pathway and 
paxillin, which upon progranulin stimulation formed a complex 
FiGURe 1 | Progranulin signaling in bladder cancer. The schematic draw summarizes the current knowledge of progranulin signaling pathways leading to 
motility and invasion of bladder cancer cells. Progranulin interaction with the unidentified progranulin membrane receptor mediates progranulin internalization and 
interaction with the F-actin protein drebrin, thus regulating MAPK and Akt pathways and cytoskeletal remodeling (40). Additionally, progranulin signaling activates 
paxillin, which may contribute with MAPK in regulating the dynamic of focal adhesions.
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with focal adhesion kinase (FAK) and active extracellular signal-
regulated kinase (ERK) at the leading edge of migrating urothelial 
cancer cells (42). These results suggested that progranulin-induced 
cell motility might be regulated by the ability of progranulin to 
modulate focal adhesion dynamics of motile cancer cells.
We later discovered that urothelial cancer cells abundantly 
secrete progranulin (39). Significantly, stable depletion by 
shRNA approaches of endogenous progranulin expressed in T24 
urothelial carcinoma-derived cell inhibited both the Akt and 
MAPK pathways, reduced the ability of T24 cells to proliferate in 
the absence of serum and inhibited motility, wound healing and 
invasion in  vitro (39). Collectively, these results demonstrated 
that progranulin acts as a tumorigenic autocrine growth factor 
for bladder cancer cells and may work as a biomarker for bladder 
neoplasms.
In order to gain further insights into the molecular mecha-
nisms of progranulin action in bladder cancer, we searched for 
novel progranulin-interacting proteins using pull-down assays 
with recombinant progranulin and proteomic analysis. We dem-
onstrated that drebrin (developmentally regulated brain protein), 
an F-actin binding protein (43, 44), interacted with progranulin 
in urothelial cancer cells (40), modulated progranulin-induced 
MAPK and Akt signaling, and promoted progranulin-dependent 
motility and invasion by regulating F-actin remodeling (40). 
In addition, drebrin was essential for anchorage-independent 
growth in vitro and tumor formation in vivo, and its expression 
was upregulated in bladder cancer tissues compared to normal tis-
sue controls (40). Our data demonstrated an essential functional 
role for drebrin in the regulation of progranulin actions suggest-
ing that drebrin may constitute a novel target for therapeutic 
intervention in bladder tumors. In addition, drebrin may work as 
novel biomarker for bladder cancer progression (Figure 1).
Given the critical role of progranulin in regulating motility 
and invasion of urothelial cancer cells (39, 40, 42), we then 
determined whether targeting progranulin could have therapeu-
tic efficacy in bladder cancer. Thus, we very recently generated 
progranulin-depleted tumorigenic urothelial cancer cells and 
demonstrated that progranulin targeting markedly reduced 
in vivo tumor growth of UMUC-3 cells in both orthotopic and 
subcutaneous xenograft tumor models (41). The immunostaining 
analysis of orthotopic tumors derived from progranulin-depleted 
UMUC-3 cells tumors had significantly lower expression level 
of Ki67, a cellular marker of proliferation, compared to tumor 
tissues derived from control-transfected cells (41). Moreover, the 
F-actin network of orthotopic tumors derived from progranulin-
depleted cells was intact and well assembled compared to con-
trols (41), supporting our previous in vitro results (40) and the 
hypothesis that progranulin might regulate invasion and motility 
of urothelial cancer cells by modulating F-actin remodeling.
Significantly, tumor tissues derived from UMUC-3/Control 
orthotopic xenografts showed reduced expression of the epithe-
lial marker E-cadherin and increased levels of the mesenchymal 
protein vimentin compared to progranulin-depleted orthotopic 
xenografts. These results would suggest that the role of progranu-
lin in bladder cancer tumor formation might be associated with 
an epithelial-to-mesenchymal transition (EMT) (45), which is 
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severely affected by progranulin ablation in urothelial cancer 
cells. These results are consistent with data showing that in OC 
progranulin induces motility and invasion through EMT and the 
activation of cancer-associated fibroblasts (20).
The standard of care for invasive and metastatic bladder cancer 
is based on platinum-containing anti-cancer drugs, such as cispl-
atin (46). Progranulin depletion significantly enhanced cisplatin-
dependent cell death as compared to control bladder cancer cells 
(41), suggesting that progranulin targeting in combination with 
cisplatin could enhance the therapeutic efficacy of cisplatin-based 
therapy in invasive bladder tumors.
Because progranulin might be secreted in the urine either 
through active secretion or after cell death, initially we assessed 
progranulin levels in concentrated urines of healthy subjects and 
demonstrated that progranulin can be detected in urine using 
immunoblots (39). Furthermore, progranulin levels in urine were 
quantified by enzyme-linked immunosorbent assay (ELISA) (39). 
Significantly, Soukup et al. (47) tested by ELISA assay the urinary 
concentrations of 27 biomarkers, including progranulin, for the 
detection of primary and recurrent urothelial bladder cancers. 
Importantly, the urinary concentration of progranulin was 
significantly higher in patients with bladder cancer compared to 
healthy subjects (47). However, progranulin levels did not show 
significant difference between patients with cancer recurrence 
and patient without recurrence (47). Taking into account the 
sample size limitation of this study, additional analyses on larger 
cohorts are necessary to establish whether progranulin may work 
as a urine biomarker for bladder cancer.
We recently analyze by immunohistochemistry progranulin 
expression levels in a human bladder tumor microarray contain-
ing 69 validated cases, including various types and stages of 
bladder cancers. Progranulin was barely detectable in normal 
bladder. In contrast, all malignant bladder tumors exhibited a 
significantly increased progranulin expression with the only 
exception of mucinous carcinoma where progranulin levels were 
comparable to normal tissues (41). Progranulin upregulation 
was not statistically different between low-grade and high-grade 
invasive urothelial carcinoma tissues (41). Progranulin was 
also upregulated in metastatic bladder tissues suggesting that 
progranulin expression levels might be associated with bladder 
cancer metastases. We additionally tested progranulin expression 
levels in archived paraffin-embedded tissues derived from non-
invasive carcinoma in situ (Tis), non-invasive low-grade papillary 
carcinomas (Ta), non-invasive high-grade papillary carcinomas 
(Ta) using as control normal, and invasive high-grade carcinoma. 
Progranulin expression levels were significantly upregulated in 
non-invasive low-grade papillary carcinomas (Ta) compared to 
benign tissues and enhanced in both non-invasive high-grade 
papillary carcinomas (Ta) and high-grade carcinoma tissues 
compared to benign tissues, while in non-invasive carcinoma 
in situ (Tis) progranulin expression was at levels similar to benign 
tissues (41). These results were somewhat surprising considering 
the importance of progranulin in regulating motility and invasion 
and suggest that progranulin expression is predictive of bladder 
tumor formation but do not discriminate between superficial and 
invasive urothelial carcinomas. On the contrary, drebrin expres-
sion correlated with bladder tumor progression (40) indicating 
that expression levels of downstream progranulin effectors may 
be more predictive of bladder tumor progression than progranu-
lin itself.
PROGRANULiN ACTiON  
iN PROSTATe CANCeR
Prostate cancer is the most common cancer in men and is also 
the second leading cause of cancer-related deaths in men (12). In 
the developed world, most prostate cancers are diagnosed at an 
early stage where the cancer is confined to the prostate or local 
organs, with minimal risk of disease progression after treatment. 
However, a significant proportion of men with clinically localized 
prostate cancer treated with radical prostatectomy will develop 
biochemical recurrence, subsequent local recurrence, and distant 
metastases (48–50). Furthermore, the mechanisms promoting 
progression to the castration-resistant stage of prostate cancer 
(CRPC) are still very poorly characterized.
We previously established that progranulin is not expressed 
in androgen-responsive LNCaP prostate cancer cells but instead 
acts as an autocrine growth factor for DU145 cells and promotes 
castration-resistant prostate cancer cell motility, invasion, and 
anchorage-independent growth (38). This study supported the 
hypothesis that progranulin was not important for prostate can-
cer initiation but might play an important role in prostate cancer 
progression and CRPC.
Sortilin, a single-pass type I transmembrane protein of 
the Vps10 family, binds progranulin in neurons and mediates 
progranulin targeting for lysosomal degradation (51). However, 
the role of sortilin in cancer is still very poorly characterized. In 
addition, whether sortilin is expressed in prostate cancer cells and 
plays any role in regulating progranulin action in prostate cancer 
has not previously established. Androgen-responsive LNCaP cells 
express very low levels of endogenous progranulin, do not respond 
to exogenous recombinant progranulin and do not express 
sortilin (52), suggesting that the progranulin/sortilin functional 
interaction may have a prevalent role in castration-resistant pros-
tate cancer. Accordingly, in castration-resistant DU145 and PC3 
cells, we detected very low levels of sortilin, which was associated 
with high levels of progranulin production and enhanced motil-
ity and invasion (52). Restoring sortilin expression in PC3 and 
DU145 cells decreased progranulin levels and inhibited motility, 
invasion, and anchorage-independent growth (52). These results 
were recapitulated by depleting endogenous progranulin in PC3 
and DU145 cells. On the contrary, targeting endogenous sortilin 
by shRNA approaches enhanced progranulin levels and sustained 
motility, invasion, and anchorage-independent growth (52).
Similar to OC, Zheng et al. (53) reported that SLPI is overex-
pressed in CRPC patients and supports CRPC cell growth and 
invasion by functionally interacting with progranulin (53). SLPI 
overexpression in prostate cancer cells provides a proliferative 
advantage after castration by its anti-protease activity toward 
elastase and protecting progranulin from elastase-dependent 
degradation (53).
These results suggest that the functional interaction between 
sortilin, SLPI, and progranulin levels may be critical for prostate 
FiGURe 2 | Sortilin-dependent regulation of progranulin action in prostate cancer. Sortilin promotes progranulin uptake through clathrin-dependent 
endocytosis and targets progranulin for degradation in the lysosomes. Sortilin loss is associated with enhanced progranulin levels and action in castration-resistant 
prostate cancer cells.
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cancer, and sortilin/SLPI loss may contribute to progranulin-
dependent action in prostate cancer progression (Figure 2).
The role of progranulin as a prostate cancer biomarker has not 
been clearly defined, and the data are also partially discordant. We 
investigated progranulin expression levels in available prostate 
cancer microarray studies using the ONCOMINE database (42). 
We found that progranulin mRNA expression was significantly 
increased in six primary prostate cancer data sets compared to 
controls (54–59). Additionally, primary tumors that have been 
treated with hormone therapy showed decreased progranulin 
mRNA levels (57). However, three studies showed contradictory 
results demonstrating that metastatic cancers had decreased pro-
granulin expression levels compared to non-metastatic prostate 
cancers (54, 55, 60).
We evaluated by immunohistochemical analysis progranulin 
expression levels in normal versus prostate cancer sections and 
demonstrated that progranulin was expressed at low levels, in 
normal prostate but was instead upregulated in tumor glands 
(42), confirming the data by Pan et al. (61), who assessed pro-
granulin (GP88) in normal prostate, prostatic intraepithelial 
neoplasia, and prostatic adenocarcinoma tissues. However, due 
to the limited sample size of both studies, additional analyses are 
indeed required to clearly define progranulin as a biomarker for 
prostate cancer progression.
CONCLUSiON
A vast body of evidence has emerged in support of the critical role 
of progranulin in promoting transformation of several cancer 
models. However, the mechanisms of progranulin action are 
still poorly characterized. Experiments are currently under way 
to identify novel regulators of progranulin signaling, which may 
constitute novel targets for therapy in tumors where progranulin 
plays a role.
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